Open Label Extension Study of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) - Full Text View

Sponsor:	Amgen
Information provided by:	Amgen
ClinicalTrials.gov Identifier:	NCT00116688

Purpose

The purpose of this study is to determine the safety of AMG 531 as a long-term treatment in thrombocytopenic subjects with ITP, to evaluate the long-term platelet response to AMG 531, and to evaluate changes in patient reported outcomes due to the use of AMG 531. Subjects must have previously completed an AMG 531 ITP study.

Condition	Intervention	Phase
Thrombocytopenia Idiopathic Thrombocytopenic Purpura	Biological: AMG 531	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title:	An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Resource links provided by NLM:

Genetics Home Reference related topics: hemophilia thrombotic thrombocytopenic purpura

Drug Information available for: AMG 531

U.S. FDA Resources

Further study details as provided by Amgen:

Primary Outcome Measures:

Incidence of adverse events, including clinically significant changes in laboratory values and incidence of antibody formation. [ Time Frame: Entire duration of the study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Duration platelet response [ Time Frame: Entire duration of the study ] [ Designated as safety issue: No ]
The proportion of subjects able to reduce or discontinue their concurrent ITP therapies (corticosteroids, danazol, azathioprine) The change from baseline in patient reported outcomes (PRO) [ Time Frame: Entire duration of the study ] [ Designated as safety issue: No ]

Estimated Enrollment:	350
Study Start Date:	August 2004
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
AMG 531: Experimental Active investigational product	Biological: AMG 531 Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 10mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.

Eligibility

Ages Eligible for Study:	1 Year and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects must have previously completed an AMG 531 ITP study
Written informed consent

Exclusion Criteria:

Bone marrow stem cell disorder or new active malignancies diagnosed since enrollment in the previous AMG 531 ITP study
Received any alkylating agents within 4 weeks before screening visit or anticipated use during the time of the proposed study
Currently enrolled in or has not yet completed at least 4 weeks since ending device or drug trial(s) (other than the previous AMG 531 ITP study), or subject is receiving other investigational agent(s) other than AMG 531.
Not using adequate contraceptive precautions
Not available for follow-up assessments
Has any kind of disorder that compromises the ability of the subject to give informed consent and does not have a legally-acceptable representative and/or is unable to comply with study procedures

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00116688

Hide Study Locations

Locations

United States, Arkansas
Research Site
Little Rock, Arkansas, United States
United States, California
Research Site
Orange, California, United States
Research Site
Pomona, California, United States
Research Site
Duarte, California, United States
Research Site
Beverly Hills, California, United States
Research Site
Berkeley, California, United States
Research Site
Los Angeles, California, United States
Research Site
La Jolla, California, United States
United States, Connecticut
Research Site
Manchester, Connecticut, United States
Research Site
Stamford, Connecticut, United States
Research Site
Fairfield, Connecticut, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Boynton Beach, Florida, United States
Research Site
Daytona Beach, Florida, United States
Research Site
Jacksonville, Florida, United States
United States, Georgia
Research Site
Albany, Georgia, United States
Research Site
Marietta, Georgia, United States
United States, Illinois
Research Site
Peoria, Illinois, United States
United States, Indiana
Research Site
Indianapolis, Indiana, United States
United States, Iowa
Research Site
Waterloo, Iowa, United States
United States, Louisiana
Research Site
Shreveport, Louisiana, United States
United States, Maryland
Research Site
Bethesda, Maryland, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, Michigan
Research Site
Bay City, Michigan, United States
Research Site
Kalamazoon, Michigan, United States
Research Site
Southfield, Michigan, United States
United States, Missouri
Research Site
St. Louis, Missouri, United States
Research Site
Kansas City, Missouri, United States
United States, Nebraska
Research Site
Omaha, Nebraska, United States
United States, New York
Research Site
Nyack, New York, United States
Research Site
Syracuse, New York, United States
Research Site
New York, New York, United States
United States, North Carolina
Research Site
Hickory, North Carolina, United States
Research Site
Pollocksville, North Carolina, United States
Research Site
Durham, North Carolina, United States
United States, Ohio
Research Site
Cleveland, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Research Site
Souderton, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Danville, Pennsylvania, United States
Research Site
Drexel Hill, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
Research Site
Radnor, Pennsylvania, United States
United States, South Carolina
Research Site
Charleston, South Carolina, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Houston, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Arlington, Texas, United States
United States, Virginia
Research Site
Abingdon, Virginia, United States
Research Site
Charlottesville, Virginia, United States
United States, Washington
Research Site
Tacoma, Washington, United States
Research Site
Seattle, Washington, United States
United States, West Virginia
Research Site
Huntington, West Virginia, United States
United States, Wisconsin
Research Site
La Crosse, Wisconsin, United States
Australia
Research Site
Box Hill, Australia
Research Site
Herston, Australia
Research Site
South Brisbane, Australia
Research Site
Perth, Australia
Research Site
Fitzroy, Australia
Australia, New South Wales
Research Site
Waratah, New South Wales, Australia
Research Site
Concord, New South Wales, Australia
Research Site
Kogarah, New South Wales, Australia
Research Site
St. Leonards, New South Wales, Australia
Research Site
Randwick, New South Wales, Australia
Research Site
Darlinghurst, New South Wales, Australia
Australia, South Australia
Research Site
Woodville, South Australia, Australia
Austria
Research Site
Wels, Austria
Research Site
Wien, Austria
Belgium
Research Site
Antwerpen, Belgium
Research Site
Leuven, Belgium
Research Site
Gent, Belgium
Research Site
Bruxelles, Belgium
Research Site
Brugge, Belgium
Canada, Ontario
Research Site
London, Ontario, Canada
Canada, Quebec
Research Site
Montreal, Quebec, Canada
Czech Republic
Research Site
Brno, Czech Republic
France
Research Site
Paris, France
Research Site
Lille, France
Research Site
Bobigny, France
Research Site
Limoges, France
Research Site
Créteil, France
Research Site
Pessac, France
Germany
Research Site
Ulm, Germany
Research Site
Gießen, Germany
Research Site
Hannover, Germany
Research Site
Essen, Germany
Research Site
Duisburg, Germany
Italy
Research Site
Vicenza, Italy
Research Site
Novara, Italy
Research Site
Napoli, Italy
Research Site
Albano Laziale, Italy
Netherlands
Research Site
Amsterdam, Netherlands
Research Site
Groningen, Netherlands
Research Site
Den Haag, Netherlands
Research Site
Rotterdam, Netherlands
Research Site
Zwolle, Netherlands
Poland
Research Site
Bialystok, Poland
Spain
Research Site
Madrid, Spain
Research Site
Valencia, Spain
Research Site
Barcelona, Spain
Research Site
Pamplona, Spain
Research Site
Badalona, Spain
United Kingdom
Research Site
Leeds, United Kingdom
Research Site
London, United Kingdom
Research Site
Truro, United Kingdom
Research Site
Gillingham, United Kingdom

Sponsors and Collaborators

Amgen

Investigators

Study Director:

Amgen

More Information

Additional Information:

AmgenTrials clinical trials website This link exits the ClinicalTrials.gov site

No publications provided by Amgen

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009 Oct 29;114(18):3748-56. Epub 2009 Aug 11.

Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009 Mar 5;113(10):2161-71. Epub 2008 Nov 3.

Responsible Party:	Amgen Inc. ( Global Development Leader )
Study ID Numbers:	20030213
Study First Received:	June 30, 2005
Last Updated:	October 22, 2009
ClinicalTrials.gov Identifier:	NCT00116688 History of Changes
Health Authority:	Australia: Human Research Ethics Committee; Australia: Therapeutic Goods Administration; Austria: AGES - PharmaMed Austria Institut Wissenschaft & Information; Austria: Bundesamt fur Sicherheit im Gesundheitswesen; Australia: Department of Health and Ageing Therapeutic Goods Administration; Austria: Bundesamt für Sicherheit im Gesundheitswesen; Austria: Central Ethics Committee; Austria: Competant Authority; Austria: Federal Ministry for Health and Women; Austria: Secretariat of Health; Belgium: Directorate general for the protection of Public health: Medicines; Belgium: Directorate-General for Medicinal Products; Belgium: Federal Public Service (FPS) Health, Food Chain Safety and Environment; Belgium: FPS of Public Health, Food Chain Security and Environment; Belgium: Pharmaceutical Inspectorate; Belgium: Service Public Federal Sante Publiquest, Securite de la Chaine alimentaire et Environnement; Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; Canada: Health Canada; Canada: Health Products and Food Branch; Canada: Institutional Review Board; Czech Republic: State Institute for Drug Control; Czech Republic: Statni ustav pro kontrolu leciv; EU: CHMP; European Union: European Medicines Agency; France and Sweden: European Medicines Agency; France: Afssaps - French Health Products Safety Agency; France: CCPPRB Central Ethics Committee; France: Ministry of Health; Germany: Federal Institute for Drugs and Medical Devices; Germany: Paul_Ehrlich-Institut Bundesamt fur Sera und Impfstoffe; Italy: Local Ethics Committees; Italy: Ministry of Health; Netherlands: CCMO (Centrale Commissie Mensgebonden Onderzoek): Central Committee Human Bound Research; Belgium: Service Public Fédéral Santé Publique, Sécurité de la Chaîne alimentaire et Environnement; Netherlands: Medicines Evaluation Board; Netherlands: Medisch Centrum Rijnmond_Zuid, lcatie Zuider; Poland: Drug Institut; Spain: Agencia Española de Medicamentos y Productos Sanitarios; Spain: Spanish Agency of Medicines; Spain: Spanish Drug Agency; Switzerland: Agency for Therapeutic Products; Switzerland: Local Ethics Committee; Switzerland: Swissmedic (Swiss Agency for Therapeutic Products); United Kingdom: Medicines and Healthcare Products Regulatory Agency; United States: Food and Drug Administration

Keywords provided by Amgen:

Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Thrombocytopenic

Additional relevant MeSH terms:

Purpura
Signs and Symptoms
Skin Manifestations
Autoimmune Diseases
Hemorrhagic Disorders
Thrombocytopenia

Immune System Diseases
Hematologic Diseases
Blood Platelet Disorders
Blood Coagulation Disorders
Purpura, Thrombocytopenic, Idiopathic
Purpura, Thrombocytopenic

ClinicalTrials.gov processed this record on November 25, 2009